BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

825 related articles for article (PubMed ID: 17710074)

  • 1. Use of antiplatelet agents and anticoagulants for cardiovascular disease: current standards and best practices.
    Faxon DP
    Rev Cardiovasc Med; 2005; 6 Suppl 4():S3-14. PubMed ID: 17710074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiplatelet intervention in acute coronary syndrome.
    Arora RR; Rai F
    Am J Ther; 2009; 16(5):e29-40. PubMed ID: 19092648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on aspirin in the treatment and prevention of cardiovascular disease.
    Hennekens CH
    Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
    Motovska Z; Kala P
    Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use.
    Reaume KT; Regal RE; Dorsch MP
    Ann Pharmacother; 2008 Apr; 42(4):550-7. PubMed ID: 18319394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.
    Prescrire Int; 2009 Oct; 18(103):193-5. PubMed ID: 19877380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.
    Toth PP
    Postgrad Med; 2009 Jan; 121(1):59-72. PubMed ID: 19179814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Individualized antithrombotic therapy in high risk patients after coronary stenting. A double-edged sword between thrombosis and bleeding.
    May AE; Geisler T; Gawaz M
    Thromb Haemost; 2008 Mar; 99(3):487-93. PubMed ID: 18327396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy.
    Rossini R; Musumeci G; Lettieri C; Molfese M; Mihalcsik L; Mantovani P; Sirbu V; Bass TA; Della Rovere F; Gavazzi A; Angiolillo DJ
    Am J Cardiol; 2008 Dec; 102(12):1618-23. PubMed ID: 19064015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolving antithrombotic treatment strategies for acute ST-elevation myocardial infarction.
    Kandzari DE
    Rev Cardiovasc Med; 2006; 7 Suppl 4():S29-37. PubMed ID: 17224888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiplatelet drugs in cardiovascular prevention: coronary events: acute phase and secondary prevention.
    Prescrire Int; 2000 Jun; 9(47):83-5. PubMed ID: 11010749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiplatelet therapy for improving post-PCI outcomes: interpreting current treatment guidelines for optimal management of the post-ACS patient.
    Cross J
    Am J Manag Care; 2009 Mar; 15(2 Suppl):S48-53. PubMed ID: 19355809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiplatelet therapy in percutaneous coronary intervention: a critical review of the 2007 AHA/ACC/SCAI guidelines and beyond.
    Cohen M
    Catheter Cardiovasc Interv; 2009 Oct; 74(4):579-97. PubMed ID: 19472347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiplatelet drug response variability and the role of platelet function testing: a practical guide for interventional cardiologists.
    Angiolillo DJ; Suryadevara S; Capranzano P; Zenni MZ; Guzman LA; Bass TA
    Catheter Cardiovasc Interv; 2009 Jan; 73(1):1-14. PubMed ID: 19089929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Percutaneous coronary intervention: assessing coronary vascular risk associated with bare-metal and drug-eluting stents.
    Spinler SA
    Am J Manag Care; 2009 Mar; 15(2 Suppl):S42-7. PubMed ID: 19355808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discharge antithrombotic strategies among patients with acute coronary syndrome previously on warfarin anticoagulation: physician practice in the CRUSADE registry.
    Wang TY; Robinson LA; Ou FS; Roe MT; Ohman EM; Gibler WB; Smith SC; Peterson ED; Becker RC
    Am Heart J; 2008 Feb; 155(2):361-8. PubMed ID: 18215609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual antiplatelet therapy and antithrombotic treatment: Recommendations and controversies.
    Bryniarski L; Pelc-Nowicka A; Zabojszcz M; Mirek-Bryniarska E
    Cardiol J; 2009; 16(2):179-89. PubMed ID: 19387970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Updates in antiplatelet agents used in cardiovascular diseases.
    Cheng JW
    J Cardiovasc Pharmacol Ther; 2013 Nov; 18(6):514-24. PubMed ID: 24213473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination antithrombotic therapy with antiplatelet agents and anticoagulants for patients with atherosclerotic heart disease.
    Arjomand H; Cohen M; Ezekowitz MD
    J Invasive Cardiol; 2004 May; 16(5):271-8. PubMed ID: 15152137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing antiplatelet therapy for the ACS patient: reacting to clinical trial data from the ISAR-REACT-2 studies.
    Steinhubl SR
    Rev Cardiovasc Med; 2006; 7 Suppl 4():S12-9. PubMed ID: 17224886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.